Dr Ashraf Zaman

Dr Ashraf Zaman

Conjoint Lecturer

PhD (Medicine), M.Sc. (Microbiology), B.Sc. (Microbiology)

Medicine & Health
School of Clinical Medicine

Dr Ashraf Zaman is a conjoint lecturer of Medicine and research fellow at the Garvan Institute of Medical Research. During his PhD at UNSW, he established the first Australian low-grade brain tumour models. Dr Zaman has been instrumental in a preclinical study that led to the repurposing of an asthma drug for the treatment of terminally ill brain cancer patients. The drug is currently being used in a clinical trial at Dana Farber Cancer Institute, Harvard Medical School. Dr Zaman is currently co-leading the ‘’ultimate weapon against brain cancer’’ project in Australia, funded by Charlie Teo Foundation. His team in Professor Joseph Powell's lab has developed the world’s largest single-cell transcriptomic dataset across major brain tumour types. The datasets are currently being used for high-throughput drug screening.  His current research focuses on transcriptomic profiling across multiple brain tumour types at single-cell resolution, spatial transcriptomics, patient-derived in-vitro (2D, organoid and bioprinting)  and in-vivo model development, drug screening and evidence-based personalised medicine.  

The Kinghorn Cancer Centre, Garvan Institute of Medical Research
  • Journal articles | 2022
    Dadario NB; Zaman A; Pandya M; Dlouhy BJ; Gunawardena MP; Sughrue ME; Teo C, 2022, 'Endoscopic-assisted surgical approach for butterfly glioma surgery', JOURNAL OF NEURO-ONCOLOGY, 156, pp. 635 - 644, http://dx.doi.org/10.1007/s11060-022-03945-5
    Journal articles | 2021
    Caixeiro NJ; Po JW; Zaman A; Sughrue ME; Teo C, 2021, 'Charlie Teo Foundation brain tumour bank', Open Journal of Bioresources, 8, pp. 1 - 8, http://dx.doi.org/10.5334/OJB.76
    Journal articles | 2021
    Noor H; Zaman A; Teo C; Sughrue ME, 2021, 'PODNL1 Methylation Serves as a Prognostic Biomarker and Associates with Immune Cell Infiltration and Immune Checkpoint Blockade Response in Lower-Grade Glioma', INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 22, http://dx.doi.org/10.3390/ijms222212572
    Journal articles | 2019
    Ha W; Sevim-Nalkiran H; Zaman AM; Matsuda K; Khasraw M; Nowak AK; Chung L; Baxter RC; McDonald KL, 2019, 'Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)', Scientific Reports, 9, http://dx.doi.org/10.1038/s41598-019-39427-4
    Journal articles | 2016
    Zaman A; Rapkins R; Nixdorf S; Teo C; McDonald K, 2016, 'TMOD-14. ESTABLISHMENT AND MOLECULAR CHARACTERIZATION OF PATIENT DERIVED CELL LINES FROM LOW GRADE GLIOMA', Neuro-Oncology, 18, pp. vi209 - vi210, http://dx.doi.org/10.1093/neuonc/now212.884

  • Charlie Teo Foundation collaborative research grant (2021-2023)
  • Charlie Teo Foundation collaborative research grant (2019-2021)
  • Higher Thinking Fund brain cancer research grant (2014-2017)

Awards and Fellowships:

  • Cure Brain Cancer Foundation PhD Scholarship, UNSW  (2014-2018)
  • UNSW TFS Scholarship (2014-2018)
  • Translational Cancer Research Network (TCRN) professional development award (2017)
  • Best poster presentation award, Prince of Wales Cliical School, UNSW (2017)
  • UNSW PRSS award (2016)
  • 2nd EMBL Australia PhD symposium award (2015)
  • Santa Lucia Foundation Fellowship, Italy (2012-2013)
  • Erasmus Mundus Mobility with Asia Award (2009-2011) 

Travel Grants:

  • 20th European Cell Death Organisation (ECDO) conference grant, Rome, Italy (2012) 
  • Joint national young researcher symposium travel grant, Rimini, Italy (2012)
  • VIBES international symposium in biosciences travel grant, Ghent, Belgium (2012)
  • Institute for Research in Biomedicine (IRB) Barcelona travel grant for cell biology and cancer medicine symposium, Spain (2011)
  • International Max Planck Research School for Molecular and Cell Biology (IMPRS-MCB) travel grant, Germany (2011)



My Research Supervision

B.Sc (Honours)


My Teaching

Cell and Molecular Biology